Endometrial Receptivity Assay (ERA) During Infertility Treatment

The endometrial receptivity assay (ERA) during infertility treatment is a relatively new diagnostic tool that is used to evaluate the receptivity of the endometrium in women undergoing IVF. This test involves taking a small biopsy of the lining of the uterus and analyzing the genetic expression of certain genes in this tissue sample.

The Benefits of ERA During IVF 

The goal of the ERA is to identify any abnormalities in gene expression that may be contributing to recurrent implantation failure, a condition in which a woman experiences multiple failed attempts at conceiving despite undergoing fertility treatments.

Research has shown that the ERA may be helpful in identifying these abnormalities and tailoring treatment protocols to better suit a woman’s individual needs. However, there is still some debate among experts about the value of the ERA in this population.

Some studies have found that the ERA does favor the use of the ERA in women with recurrent implantation failure, while others have been more cautious in recommending its widespread use.

Who Should Have an ERA ?

Ultimately, the decision to use the ERA should be based on a careful assessment of each individual patient’s history, risk factors, and treatment goals. Your healthcare provider can help you determine whether the ERA is a good option for you based on your specific needs and circumstances.

It’s also important to keep in mind that while the ERA may be helpful in identifying certain factors that contribute to recurrent implantation failure, it is not a cure-all solution. Other factors, such as sperm quality, egg quality, and overall health and lifestyle factors, can also play a role in determining a woman’s chances of conceiving successfully.

Our goal is to help you achieve a healthy pregnancy. If you are experiencing recurring implantation failure, we are here to help. Please contact us to set up a time to talk!